Effects and mechanism of miR-214 on hepatocellular carcinoma.
作者： Li-Li Zhang , Yan-Jun Guo , Chun-Na Zhao , Jian-Yun Gao
DOI: 10.1016/S1995-7645(14)60350-3
关键词:
摘要: Abstract Objective To explore the role of miR-214 in progression hepatocellular carcinoma (HCC) and its inhibitory mechanisms depressing signaling pathway β-catenin, this study was conducted. Methods We ectopically expressed HepG2 cells to obtain cell lines Lv-miR-214-HepG2 their control Lv-control-HepG2. Differences between two were compared growth, proliferation, colony forming ability cycles. RT-PCR method applied for quantification β-catenin mRNA expression. Western-blot determination protein level downstream targets (ie. Cyclin D1, c-Myc TCF-1). The effect on further explored through RNA interference restoring Results In comparison with negative (Lv-control-HepG2) blank (HepG2) control, a significant inhibition growth proliferation caused by observed after 48∼72h culture experiments ( P 0 /G 1 phase [(70.32±3.12)%] but lower proportion S [(18.42±2.90)%] >0.05). By comparing results treatment led slightly decrease expression >0.05), an extremely c-Myc, TCF-1 Conclusions functions as suppressor during HCC, achieved down-regulating pathway.
sci-hub.se 参考文章(32)
Fang Wang, Min Liu, Xin Li, Hua Tang, MiR‐214 reduces cell survival and enhances cisplatin‐induced cytotoxicity via down‐regulation of Bcl2l2 in cervical cancer cells FEBS Letters. ,vol. 587, pp. 488- 495 ,(2013) , 10.1016/J.FEBSLET.2013.01.016
Zhaoyang Liu, Kangsheng Tu, Qingguang Liu, Effects of microRNA-30a on migration, invasion and prognosis of hepatocellular carcinoma FEBS Letters. ,vol. 588, pp. 3089- 3097 ,(2014) , 10.1016/J.FEBSLET.2014.06.037
Sara Toffanin, Yujin Hoshida, Anja Lachenmayer, Augusto Villanueva, Laia Cabellos, Beatriz Minguez, Radoslav Savic, Stephen C. Ward, Swan Thung, Derek Y. Chiang, Clara Alsinet, Victoria Tovar, Sasan Roayaie, Myron Schwartz, Jordi Bruix, Samuel Waxman, Scott L. Friedman, Todd Golub, Vincenzo Mazzaferro, Josep M. Llovet, MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a Gastroenterology. ,vol. 140, pp. 1618- 1628 ,(2011) , 10.1053/J.GASTRO.2011.02.009
Xiao Zhang, Shijie Hu, Xiang Zhang, Lei Wang, Xiaofang Zhang, Bo Yan, Jing Zhao, Angang Yang, Rui Zhang, MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications. ,vol. 443, pp. 1078- 1084 ,(2014) , 10.1016/J.BBRC.2013.12.095
Carlo M. Croce, Causes and consequences of microRNA dysregulation in cancer Nature Reviews Genetics. ,vol. 10, pp. 704- 714 ,(2009) , 10.1038/NRG2634
Diane M. Pereira, Pedro M. Rodrigues, Pedro M. Borralho, Cecília M.P. Rodrigues, Delivering the promise of miRNA cancer therapeutics Drug Discovery Today. ,vol. 18, pp. 282- 289 ,(2013) , 10.1016/J.DRUDIS.2012.10.002
Silvia Giordano, Amedeo Columbano, MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?† Hepatology. ,vol. 57, pp. 840- 847 ,(2013) , 10.1002/HEP.26095
Hongping Xia, London Lucien PJ Ooi, Kam M Hui, None, MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma PLOS ONE. ,vol. 7, ,(2012) , 10.1371/JOURNAL.PONE.0044206
Zhengyu Xu, Tao Wang, miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1 Biochemical and Biophysical Research Communications. ,vol. 449, pp. 190- 195 ,(2014) , 10.1016/J.BBRC.2014.04.140
Yi W Kong, David Ferland-McCollough, Thomas J Jackson, Martin Bushell, None, microRNAs in cancer management. Lancet Oncology. ,vol. 13, ,(2012) , 10.1016/S1470-2045(12)70073-6